Research

Our research is built around a single conviction: cancer is an evolutionary reversion that can be reversed at the source. The lead platform is the NKG2D-LIF6 chimera.

NKG2D-LIF6 Chimera

2,123 bp · single construct · AAV9-deliverable

A chimeric receptor-effector construct fusing the human NKG2D extracellular domain (which binds the stress ligands MICA and MICB selectively upregulated on solid tumor cells) to elephant LIF6 — the re-functionalized pseudogene that mediates rapid mitochondrial apoptosis and explains Peto's Paradox in elephants (Vazquez et al. 2018, Cell Reports).

Architecture

Recognition module: NKG2D ECD (residues 79-216) — binds MICA/MICB tumor-stress ligands
Linker: Optimized P2A self-cleaving peptide
Effector module: Codon-optimized elephant LIF6 with retained mitochondrial localization signal
Delivery: Single AAV9-encoded payload, IV administration

⚠ Stage disclosure: Every numerical or biological claim on this page is a computational prediction. There is currently no in vivo data, no human data, no peer-reviewed publication of the NKG2D-LIF6 chimera. Wet-lab validation begins Q3–Q4 2026 across CRC, melanoma, and pancreatic syngeneic murine tumor models. Methods and code will be open-sourced under CC BY 4.0 at github.com/nightbox-llc/chimera-design-notes.

In Silico Validation (computational only)

Predicted ~99% tumor growth inhibition ceiling on CRC models
Selectivity ratio > 10³ tumor vs. healthy tissue (modeled MICA/MICB expression atlas)
Folding stability confirmed in human cellular context (AlphaFold + Rosetta refinement)
Competitive intelligence scan: clean IP whitespace on the specific chimera

Scientific Rationale

Most "elephant biology into therapy" projects deliver TP53 — the upstream sensor. We deliver LIF6 — the downstream killer. TP53 is a pleiotropic transcription factor with hundreds of downstream targets and timing dependencies. LIF6 is a single-purpose mitochondrial puncher with cleaner pharmacology and faster kill kinetics.

By fusing LIF6 to NKG2D's ligand-binding domain, the effector is only triggered in cells that express the stress signature characteristic of solid tumors. This bypasses the manufacturing complexity of CAR-T while maintaining selectivity.

Open Questions

NKG2D ligand shedding by tumors as escape mechanism
On-target/off-tumor toxicity from NK and γδ T cell engagement
Folding behavior of elephant LIF6 in human cellular context (long-term)
Optimal AAV serotype for solid tumor biodistribution

Researchers, clinicians, and prospective collaborators: please reach out to artem@nightboxllc.com.